rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SABSW
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      SAB Biotherapeutics at UBS conference: late-stage diabetes bet
      Nov 17Investing.comSABSSABSWUBS
      SAB BIO at Jefferies Global Healthcare Conference: type 1 diabetes push
      Nov 16Investing.comSABSSABSWJEF
      What SAB Biotherapeutics (SABS) Said on Its Q3 Earnings Call
      Nov 6Yahoo FinanceSABSSABSW
      SAB Biotherapeutics Inc (SABS) (Q3 2026) Earnings Call Highlights: FDA Fast-Track Win, Full ...
      Nov 5Yahoo FinanceSABSSABSW
      SAB Biotherapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaSABSSABSW
      SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
      Nov 5Yahoo FinanceSABSSABSW
      SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
      Oct 23Yahoo FinanceSABSSABSW
      SAB Biotherapeutics Says SAB-142 Receives FDA Fast Track Designation in Type 1 Diabetes
      Oct 13Yahoo FinanceSABSSABSW
      SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

      Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes MIAMI, Oct. 13, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAB-142, a potential

      Oct 13Yahoo FinanceSABSSABSW
      SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
      Sep 22Yahoo FinanceSABSSABSW
      SAB BIO at Citi summit: trial progress and a bigger t1d bet
      Sep 10Investing.comSABSSABSW
      SAB BIO to Participate in Upcoming Investor Conferences
      Sep 1BarchartSABSSABSW

      This is the newest page. Registered accounts read further back.